Interferon Beta-1b Drug Asset Due Diligence Report 2026

This Interferon Beta-1b Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Interferon Beta-1b can convert its Interferons profile and Type I IFN Receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Interferon Beta-1b (query alias: interferon beta-1b)
Modality / target	Interferons; Type I IFN Receptor; IFNAR agonists, Immunomodulators
Highest global status	Approved
Originator	Chiron Corp.
Active developers	Novartis Pharmaceuticals Corp., Bayer AG, Bayer Yakuhin Ltd.

The MCP disease footprint includes Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
IRCT20201001048894N1	Phase 2/3	Complete	90	Not disclosed
NCT04647695	Phase 2	Unknown status	100	Clinical improvement
NCT04494399	Phase 2	Unknown status	96	Clinical symptoms alleviation

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pregnancy Outcomes in Adolescent/Young Adult Patients With Multiple Sclerosis

Not Applicable; n=14; evaluation: Positive. Reported fields: Postpartum depression (PPD) = 21 % ; Postpartum depression (PPD) = 21 % ; Postpartum depression (PPD) = 21 %

Plasma NET markers kinetics in COVID-19 patients receiving immunomodulatory treatments: a cohort study

Phase 2/3; n=225; evaluation: Positive. Reported fields: H3Cit = inhaled IFN-β-1b, but not inhaled ciclesonide nor placebo, was linked to a decrease in plasma H3Cit levels (p: 0.02). ; H3Cit = inhaled IFN-β-1b, but not inhaled ciclesonide nor placebo, was linked to a decrease in plasma H3Cit levels (p: 0.02).

Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial.

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: Develop seropositive IgG = 10 day ; Develop seropositive IgG = 8 day

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Interferon Beta-1b addresses Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interferons—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-04-21	Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments	Approved	US$1.1M stated total
2007-09-14	Novartis Completes Agreement With Bayer Schering Related To Betaseron Rights And Manufacturing	Approved	US$200.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO